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 Irritable Bowel Syndrome (IBS) is one of the most common diagnoses made in primary 
care accounting for approximately12% of all visits; further estimates report upwards of 20% of 
American have IBS. Patients present initially with abdominal pain and alteration in bowel 
movements that are dominant in constipation, diarrhea, or alternating between the two. These 
symptoms cause changes in health-related quality of life. Although several theories exist the 
cause of IBS is unknown; therefore, there is no cure, only management of symptoms. Currently, 
symptom management based on IBS subtype with multiple pharmacologic agents is the norm. 
Although antispasmodics have been reported as effective, the choice of pharmacotherapy 
remains largely subjective based on patient response and ultimately the provider patient 
relationship influences the choices offered. Probiotics (live bacteria) are an emerging therapy 
option with no serious adverse reactions. Their ability to improve quality of life for the patient by 
way of reducing symptoms of abdominal pain and bloating, passing of flatus, and incomplete 
evacuation/straining is significant. Bifidobacterium infantis has the potential to significantly 
reduce IBS related healthcare costs and provide a resource for the primary care provider other 
than sending the patient to Gastroenterology for evaluation. Probiotic use in primary care is a 
safe option for treatment of IBS.  
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   Management of Irritable Bowel Syndrome in Primary Care 
Introduction to Irritable Bowel Syndrome 
 The American College of Gastroenterology Task Force, 2009, has estimated that 7-10% 
of the population in the United States (US) has Irritable Bowel Syndrome (IBS) making it more 
common than asthma or diabetes. Further estimates report upwards of 20% leaving one in five 
Americans with this disorder (Wald and Rakel, 2008). Approximately 5-7% of individuals with 
IBS are aware of their diagnosis while the remainder of the population remains undiagnosed yet 
symptomatic (Hungin, Whorwell, Tack, & Mearin, 2003). IBS is a compilation of altered bowel 
habits over a period of time and includes abdominal pain and discomfort. The effects of IBS are 
widespread. It is known that IBS is one of the most common diagnoses made in primary care 
accounting for approximately12% of all visits. In addition, a survey conducted by Russo, 
Gaynes, and Drossman (1999) found IBS to be the most common functional GI diagnosis 
comprising 35% of all outpatient referrals to gastroenterologists. This makes IBS the most 
common diagnosis for gastroenterologists as well. This trend continues with IBS accounting for 
20%-50% of visits to gastroenterologists (Wald & Rakel, 2008). The current shortage of 
gastroenterologists has led to the need to diagnose and manage IBS in the primary care setting. 
 IBS sufferers present initially to primary care with abdominal pain and alteration in 
bowel movements that are dominant in: constipation (IBS-C), diarrhea (IBS-D) or mixed (IBS-
M). They report straining, urgency or sensation of incomplete evacuation. These symptoms 
result in missed school and work days, decreased productivity, and missed social interactions. 
There is altered food intake, diminished desire to eat and changes related to food choices. IBS 
patients undergo more abdominal surgeries than the general population including: 
appendectomies, cholecystectomies, and hysterectomies. They also confront challenges from the 
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syndrome’s complications resulting in a decreased health-related quality of life comparable to 
other major diseases including diabetes and kidney disease (El-Serag, Olden, & Bjorkman, 
2002). Therefore, the most troublesome complication of IBS is the impact on health-related 
quality of life for those suffering with this diagnosis. Although IBS does not cause mortality in 
its sufferers its impact on quality of life has been linked to suicidal behaviors (Spiegel, 
Schoenfeld, and Naliboff, 2007). 
 Even after a diagnosis is made management of the disease and its resulting alterations in 
quality of life remain troublesome for patients and providers. There are many treatment options 
to consider. The majority of these remain focused on symptom management; however, further 
options include the use of antidepressants, antibiotics and emerging evidence on the efficacy of 
probiotic use on digestive microflora restoration.  
Definition 
 Bockus, Bank, and Wilkinson (1928) were the first to describe IBS by defining its 
pathogenesis with the term neurogenic mucous colitis. Since its discovery IBS has been referred 
to by many different names including nervous colitis, spastic colon, spastic bowel and functional 
bowel disease (American Gastroenterology Association, 2010). Colitis however, is an 
inflammation of the colon which is not evident in IBS. It is clearly documented that IBS does not 
cause permanent damage to the intestines and does not lead to other serious organic diseases. 
 Diagnosing IBS is complicated as it is considered a syndrome rather than a definitive 
organic disease with a specific course and medical management. Sufferers exhibit 
chronic/recurrent motility disorders of the small and large intestines without organic pathology 
or anatomical abnormalities. Historically, IBS becomes the diagnosis when all other more severe 
diseases have been ruled out.  It is associated with severe discomfort and presents with 
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abdominal pain and distention in association with alterations in defecation. Individuals with IBS 
have increased intestinal sensitivity which may exacerbate symptoms. Heredity, psychosocial 
factors, nutrition, and inflammation or infection have been proposed to contribute to IBS 
(Drossman, 2006).The American College of Gastroenterology Task Force (2009) has proposed 
that the best way to define IBS is by defining what it is not. IBS is not an anatomical or structural 
problem, an identifiable physical or chemical disorder, a malignancy, nor will it cause cancer, a 
precursor of other gastrointestinal diseases, and something you have to” just live with”. 
Conversely a definition of what IBS constitutes is based on Rome Criteria. The Rome 
Foundation, beginning in 1989, is an international effort via a nonprofit organization that meets 
in Rome to establish evidenced-based data criteria for the diagnosis and management of 
functional gastrointestinal disorders including IBS.  IBS includes a recurrence of abdominal pain 
or an uncomfortable sensation in the abdomen. To be classified as IBS, the abdominal discomfort 
will have a defined onset of at least six months and duration of at least 3 months. It is associated 
with at least two of the following symptoms: improvement of abdominal discomfort with 
defecation, and a change in the frequency or form of stool. 
Epidemiology 
 As a chronic disease the effects of IBS can span the lifetime. Approximately 50% of 
people with IBS report symptoms beginning before they were 35 years-old, and many date the 
symptoms back to childhood.  Although IBS is prevalent among young adults under 50 years-old 
(American College of Gastroenterology Task Force, 2009) it is not seen as a primary diagnosis 
after age 50. IBS occurs 1.5 times more frequently in women than men (American College of 
Gastroenterology Task Force, 2009).It remains unclear if this s a true prevalence or if men 
simply seek medical care less often than women. IBS occurs more frequently in lower 
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socioeconomic groups and it has a graded decrease in prevalence with increasing income 
(Andrews et al., 2005). While American and European cultures demonstrate similar frequency of 
IBS across racial and ethnic lines, discrepancies in prevalence are seen in non-western countries 
in south Asia and the Middle East. This is possibly related to the tools utilized having a lack of 
cultural adaptation (Khoshkrood-Mansoori et al., 2009).  
 Regardless of ethnic background in the US, IBS patients have a higher utilization of 
physician visits, diagnostic tests, and medications (Everhart & Renault, 1991). Costs for IBS 
reach over $20 billion in both direct and indirect costs (American Gastroenterology Association, 
2001). Patients with IBS have more missed worked days and lower work productivity than their 
healthy counterparts. These issues are expected to remain prevalent in the United States in future 
years. Current healthcare reform, potentially giving access to the underinsured and uninsured, 
will add further burden. Hence, diagnosis of IBS, management of its symptoms, and 
consequences of its complications will require an increasing amount of financial and healthcare 
resources. In an effort to reduce healthcare consumption research regarding IBS is focused on the 
effects of probiotics, dietary intake and stress management. 
Pathophysiology 
 Probiotics, dietary intake and stress management are able to directly affect the large 
intestine based on the anatomy and physiology of the colon. The colon is approximately six feet 
long and two inches in diameter. It connects the small intestine with the anus. The colon wall 
consists of four layers: serosa, muscularis, submucosa and mucosa. Haustra occur through 
periodic uncoordinated tonic contractions which bunch up the mucosa and propel stool. The 
submucosa is made up of loose connective tissue and contains veins, arteries, lymphatic vessels, 
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nerve fibers and ganglion cells. The inner mucosa layer is a smooth absorptive surface lined with 
columnar epithelial cells and goblet cells. 
 The composition of the colon wall assists in the function of the colon which includes: 
storage, movement of contents, absorption of water, electrolytes and bile acids and a minor role 
in the excretion of mucus, potassium, and bicarbonate. Colon movement is controlled by nerves, 
hormones and electrical activity in the colon muscles. Stimulation of the parasympathetic nerves 
increases intestinal contraction and mucus secretion and inhibits the rectal sphincter. Stimulation 
of the sympathetic nerves inhibits colonic motility and secretions while stimulating the rectal 
sphincter. 
 While the exact cause of alteration in transit is unclear it is known to be classified as 
irritable due to consistent underlying abnormalities in motility and visceral sensitivity. Theories 
exist to identify the role in the development of IBS. These theories include: a) CNS influenced 
altered bowel motility affecting both secratory and immune functions; b) visceral 
hypersensitivity related to the autonomic nervous system; c) psychosocial factors; d) 
neurotransmitter imbalance affecting the sympathetic and parasympathetic pathways as well as 
their communication with the CNS; and e) post-infection and inflammation resulting in alteration 
in the microflora of the colon and immune hypersensitivity. None of the theories explains all of 
the symptoms of IBS. 
 IBS symptoms are subtyped into IBS-C, IBS-D or IBS-M. Research has been mainly 
focused on the motility of the gastrointestinal tract. Altered contractility of the longitudinal or 
circular muscles appears to be related to exaggerated patterns of intestinal motility, causing 
either diarrhea or constipation based on which muscles type spasms with the most force. IBS is 
thus classified as diarrhea- fast-colonic transits, constipation- slow colonic transit, or mixed 
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classifications. There is a wide range of normal findings, from daily bowel movements to only a 
couple a week, with no definitive colonic transit time is the set normal. Several factors are 
associated with altered motility including; physical or psychological stress, dietary intake of 
lactose or high fat meals or fasting. The study of large and small intestine transit time has been 
and remains subjective. 
 Objectively, physiologic stimuli in the gut elicit reflex responses to perform digestive 
function. The gastrocolonic reflex normally occurs 30-45 minutes after a medium sized meal. 
Normally this occurs unnoticed, but in IBS pain, discomfort and altered bowel function exist 
related to perception in the gastrointestinal (GI) tract. Patients feel pain disproportionately due to 
changes with afferent signals from the dorsal horn neurons through the ascending pathways 
suggesting a central pain processing defect. Pain is a major component of IBS. Researchers have 
used balloon inflation in the colon via computerized barostat and been able to detect increases in 
cerebral cortical activity (Truong, Naliboff, & Chang, 2008) Further studies have found that IBS 
patients are able to detect the inflating balloon at much lower levels of inflation than those 
without IBS. This increase is noted with rapid rather than gradual distention. Subjectively, IBS 
patients have also reported that they have more gas-like sensations; however, when this has been 
studied, IBS patients have the same amount as non-IBS controls (Hernando-Harder et al., 2010).  
 Further subjective findings are related to psychosocial factors. Increased sympathetic 
nervous system activity and decreased parasympathetic nervous activity have been noted in 
people with IBS. This supports that the autonomic nervous system can modulate visceral 
sensitivity and the central nervous system can influence the motility and secratory activity of the 
GI tract by way of autonomic pathways via the enteric nervous system (Bockus et al., 1928). 
Through the three divisions of the autonomic nervous system the sympathetic, parasympathetic, 
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and enteric systems, GI motility, secretion and immune function are adjusted and coordinated 
(Hansen, 2003). Although the production of secretions is scant in the colon it is important to 
remember that the alkaline mucus lubricates the intestinal walls promoting stool passage and 
protects the mucosa from acidic bacteria. Adaption of the autonomic nervous system, including 
increased sympathetic nervous system action and decreased parasympathetic nervous system 
action is an important part of the body’s response to stress. Increased stress results in GI function 
producing IBS symptoms.  
 Neurotransmitter imbalance may also contribute to IBS symptoms. Serotonin is a key 
neurotransmitter influencing bowel contractility and visceral hypersensitivity. Serotonin may 
provide a link between the enteric and central nervous systems. It has been postulated that people 
with IBS process CNS input differently than those without IBS.  
 CNS stimulation in the form of psychopathological disorders such as hypervigilence 
regarding bowel function, stress, anxiety, somatization, panic disorders or depression may also 
contribute to alterations in CNS processing. Patients with psychological disturbances have been 
documented to have more debilitating illnesses and are often referred to as hypochondriacs. 
Pychopathological disorders may also be linked to environmental factors to the extent that 
children learn behaviors modeled by their parents (Drossman, 2006). Motility disturbances have 
been found to correspond to an increase in hypothalamic corticotropin-releasing factor (CRF) 
production in response to the stress response. The connection between IBS exacerbations and 
psychosocial occurrences remains poorly understood (Longstreth et al., 2006). Interestingly, 
Axis I disorders coexists with GI symptoms in up to three quarters of patients. Therefore, a shift 
in the treatment of IBS to include treatment of psychopathological disorders has proven effective 
for some people. Heitkemper, Cain, Burr, Jun, and Jarrett (2010) propose a link between 
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childhood neglect and sexual abuse and IBS, an important factor to consider. Although research 
suggests psychological disturbances may exacerbate GI distress; they do not definitively cause 
IBS. 
 IBS commonly follows an episode of infectious gastroenteritis. In a retrospective study 
by Chaudhary and Truelove (1962) a significant portion of the study participants whom reported 
onset of IBS symptoms following an episode of gastroenteritis. Thabane, Kottachchi, and 
Marshall (2007) conducted a systematic review and meta analysis and found to be a six-fold 
increase in the development IBS after gastroenteritis. Additionally, the risk for development of 
IBS remained elevated for 2-3 years after the infectious process has ended. This is related to 
persistent sub-clinical inflammation which injures the enteric nervous system causing alterations 
in small intestinal permeability and gut flora. An example is traveler’s diarrhea and then 
resulting IBS-D. The injury can lead to chronic mucosal inflammation which culminates in 
dysmotility. Hence, a pathogen causing gastroenteritis is able to disrupt intestinal flora altering 
the barrier function it provides by increasing permeability, and causes neuromuscular 
dysfunction with alterations in motility while eliciting chronic inflammation (Thabane & 
Marshall, 2009). Alterations of the gut flora during and after an infectious process are thought to 
be synergistic to the inflammation altering the enteric nervous system and alterations in intestinal 
permeability. Current research focuses on how probiotics can assist in promoting intestinal 
health and preventing or diminishing the effects caused by gastroenteritis. The phenomena of 
post-infectious IBS exist; however, biopsies from IBS patients do not show alteration in mucosa. 
This leaves this hypothesis unlikely and in need of more research. Furthermore, these patients 
appear to have spontaneous albeit gradual resolution of their IBS symptoms verses the chronic 
symptoms of other IBS sufferers.  
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  A final IBS theory is that recurrent exposure to otherwise benign substances may produce 
an autoimmune inflammation response which is thought to lead to an alteration in motility. In 
their study based on IgG food sensitivity Atkinson, Sheldon, Shaath, and Whorwell (2004) found 
that elimination of the offending food produced a clinical decrease in reported symptoms. 
O’Mahony et al., (2005) compared the response of symptoms and cytokine ratios in IBS patients 
after probiotic dosing and reported interleukin-10 and interleukin-12, a monitoring tool for an 
anti-inflammatory state, was initially elevated and was found to normalize to a pro-inflammatory 
state after intake of the probiotic. The alteration of colonic flora and the connection between the 
mind and the body has shown to be increasingly significant in the pathogenesis of IBS and 
important in the determination of diagnosis and treatment of the syndrome. 
Presentation 
 Diagnosis and treatment are based on the presentation of IBS. Supportive symptoms that 
relate to the diagnosis of IBS include: stool frequency, abnormal stool formation, and stool 
consistency as determined by the Bristol Stool Form Scale (Lewis & Heaton, 1997). The Bristol 
Stool Form Scale is presented in Figure 1 located in Appendix B. This is an important tool in 
providing continuity in stool consistency definitions, as what a patient reports as diarrhea or 
constipation may not be classified as such according to the scale. There may also be a feeling of 
incomplete evacuation, passage of mucus, and bloating. 
 The presence of abdominal pain is also required for IBS diagnosis. Pain is somehow 
related to defecation and can be described as crampy/sharp, burning, diffuse/radiating, 
continuous achy, or sharp exacerbation. The location varies by patient, but remains consistent for 
the individual. Most people present with sigmoid discomfort and suprapubic pain with radiation 
towards the rectum. Some refer to “labor-like pains” and less commonly, pain that radiates 
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toward their legs. Some will refer to a belt-like pain radiating from the left lower quadrant to the 
midline. Timing of the pain is unpredictable aside from a correlation with increased stress. 
Although post prandial fullness is common, it is usually relieved with defecation. It is common 
for people to report no pain at night while asleep and then an increase in pain while awake.  
         Although the pain follows predictable patterns relating to sleep/wake cycles it raises 
concern for the sufferer. People with IBS appear to be hyper vigilant about their stool 
consistency and frequency with an emphasis on a fear of anatomic abnormalities like colon 
cancer. Normal defecation ranges from three bowel movements a day to three a week. Criteria 
for the diagnosis of IBS are abdominal pain or discomfort coupled with altered bowel function 
over a period of at least three months. 
 The Rome III Criteria, reported by Chang (2006) and Drossman (2006), is the most 
current method for IBS identification. The Rome III effort encompassed 14 committees made up 
of 87 participants. The committees were divided into issues of gender, society, patient, social 
issues, pharmacology and pharmacokinetics with all committee work culminating in the final 
meeting in Rome. Rome III criteria include: a) frequency for threshold of symptoms; b) duration 
of symptoms; and c) refining the subtyping of IBS.  
          Once diagnosed, Rome III Criteria also classifies IBS into a predominant subtype based on 
presenting symptoms (Table 1) and the frequency of the alteration of stool pattern. Stools may be 
compressed and pencil-like due to rectosigmoid spasm. An IBS-C person may have scybala a 
dehydrated pellet-like stool. Often IBS-D is considered when soft stool is passed with gas. Fecal 
incontinence, an extreme of IBS-D, occurs in 20% of patients. It is associated with reflex 
relaxations associated with repetitive spastic distal colonic contractions. An IBS-M patient would 
describe a presentation which alternates between IBS-C and IBS-D.  





Predominant Stool Pattern Subtyping of Irritable Bowel Syndrome         
 Pattern Definition 
Subtype   
IBS with constipation 
(IBS-C) 
 
Hard or pellet stools ≥25% and loose or watery stools <25% of 
bowel movements. 
 
IBS with diarrhea (IBS-D) 
 
Loose or watery stools ≥25% and hard or pellet stools <25% of 
bowel movements. 
 
Mixed IBS (IBS-M) 
 
Hard or pellet stools ≥25% and loose or watery stools ≥25% of 
stools. 
 
Note: Based on Rome Foundation Definition (2010)  
 A further classification, important in the clinical setting, is that of severity which includes 
more than just symptoms. Lembo, Ameen, and Drossman (2005, p. 717), due to lack of IBS 
severity consensus, proposed “components of IBS severity include symptom intensity, time of 
assessment, whether the patient or physician (provider) makes the severity determination, the 
type of scale used to measure severity, and the degree of disability or impairment”.  Lembo et al.  
further hypothesized that severity can be divided into “components including health-related 
quality of life, psychosocial factors, healthcare utilization behaviors, and burden of illness” 
(p.717). Although it is subjective to the population studied an indicator that IBS severity may be 




greater than previously acknowledged is the finding that the prevalence of severe or very severe 
IBS range from 3%-69% (Lembo et al., 2005).  
 Bloating, belching and abdominal distention are common associated complaints and 
happen regardless of meal consumption. It has been shown that people with IBS do not have 
more gas than people without IBS they just have intolerance. Jiang, Locke III, Choung, 
Zinsmeister, Schleck, and Talley (2008), while researching risk factors for abdominal bloating 
and visible distention found that bloating was a subjective sensation and distention is objective; 
however, these two phenomena have similar risk factors including an increase during times of 
stress. Furthermore, Jiang et al. found that 19% of the population experience bloating and about 
half of those with bloating who also experience distention were predominantly from the IBS-C 
group. Bloating is referred to as hepatic flexure syndrome and splenic flexure syndrome as these 
are the highest areas of the colon when upright and the passage of flatus relieves this discomfort. 
Bloating and distention have both been found to arise from an alteration in microflora. Related 
complaints include heartburn, indigestion, epigastric pain and nausea.   
 Corsetti, Caenepeel, Fischler, Janseens, and Tack (2004) reported that 13-87% of patients 
with either the diagnosis of IBS or functional dyspepsia (FD) fulfill the criteria of the alternate 
diagnosis. There may be a distinct subgroup with the diagnosis of both IBS and FD (Wang et al., 
2008). Currently, 13%-87% of people with either FD or IBS are able to fulfill the criteria for the 
alternate diagnosis (Corsetti et al., 2004). Other extra-intestinal symptoms include increased 
urination frequency, dyspareunia and decreased libido. Symptoms are often exacerbated during 
the premenstrual period. Fibromyalgia is the only current co-morbidity (Longstreth et al., 2006). 
 Symptoms of IBS are seen in several disease processes and many patients are diagnosed 
with IBS only after suffering with symptoms for several months to years. On physical 




examination most people will appear to be normal, although often somewhat anxious, and may 
have a palpable sigmoid cord or tenderness in the abdomen. Therefore an elusive presentation 
can make for a challenging diagnosis.  
Diagnosis 
 IBS should not be a diagnosis of exclusion and yet it often is. There is no “Gold 
Standard” test to identify the etiology of and manage IBS. Rome III Criteria of functional 
gastrointestinal disorders is used as a guide for the diagnosis of IBS (Drossman, 2006).  Use of 
the Rome Criteria for diagnosing IBS by non-gastroenterologists including surgical specialists 
has been poor (Charapata & Mertz, 2006). Changes in education have been made and functional 
gastrointestinal disorders are now addressed in undergraduate and postgraduate training as well 
as in clinical settings (Drossman, 2006). In an effort to have more non-gastroenterologists feel 
confident diagnosing IBS there is increasing international recognition and educational offerings 
related to IBS (Drossman, 2006). 
 Although training and recognition are growing; tests are still utilized to rule-out other 
diseases as IBS cannot be diagnosed by physical, radiologic, or endoscopic examination, or by 
laboratory tests (Bellini et al., 2005) Unnecessary, expensive and invasive diagnostic tests are 
often performed. These tests may include blood draws, colonoscopies, and imaging such as CT’s 
of the abdomen and pelvis. Longstreth and Yao (2004) found IBS patients were three times more 
likely to undergo unnecessary abdominal surgeries. The American College of Gastroenterology 
Task Force (2009) recommend diagnostics for patients presenting with IBS symptoms (Refer to 
Table 2 and Figure 2 located in Appendix C) including: a) Complete blood count (CBC) with 
differential to screen for anemia, inflammation, and infection; b) Blood chemistry (CHEM-10) to 
evaluate for metabolic disorders and to rule out dehydration/electrolyte abnormalities in patients 




with diarrhea; c) Liver Function Test; d) erythrocyte sedimentation rate to check for 
inflammation; e) Thyroid Function studies; f) stool for ova and parasites; and g) Serologic Celiac 
Sprue testing. Imaging recommendations include screening colonoscopy in those which are 
symptomatic or over 50yo/ 45yo for African Americans. Hemoccult stool testing or fecal 
immunochemical testing (FIT) can be performed to rule out occult blood in those who do not 
meet criteria for or refuse colonoscopy. Most importantly however is to focus on a thorough 
history. This will identify timing and circumstances related to the visit in addition to stool 
characteristics. In contrast a sudden change from an established pattern would require further 
testing and consideration of other problems.  
 The current Rome III Criteria are helpful, yet practitioners report concern regarding 
differential diagnoses. Symptoms indicative of an alternate diagnosis include red flags such as 
pain or diarrhea that wakes the patient from sleep, blood in the stool, weight loss, family history 
of cancer, fever, or abnormal findings on the physical examination (Torii & Toda, 2004). 
Diagnosis of IBS is dependent on meeting the Rome III Criteria and excluding differential 
diagnoses. 
Table  2  
Invasive verses Non-invasive Tests 
Non-Invasive Tests Invasive Tests 
Stool for Ova and Parasites CBC with differential 
Stool for Clostridium Difficile toxin CHEM- 10 
Hemoccult Stool Liver Function Test 
FIT Testing Erythrocyte Sedimentation Rate 






Current Pharmacologic Options 
 Once differential diagnoses are ruled-out the provider is left with the presenting 
symptoms which are mainly subjective. There is no standardization of care for IBS only 
treatment of the symptoms. Some drugs have evidence of working on more than one symptom. 
In many instances the effect of the drug is also subjective therefore evidence can be found to 
support the use of several drug classes.  
 
 
Abdominal Imaging- Small Bowel Barium 
Follow through or computed tomography of 
the abdomen or pelvis 
Thyroid Function Studies 
Gallbladder Ultrasonography Serum Calcium (hyperparathyroidism) 
Hydrogen Breathe Test Serologic Celiac Sprue 
Breath Testing- Screen for lactose/fructose 
intolerance 
Esophogastroduonenoscopy 
 Small bowel biopsies for celiac disease 
 Flexible Sigmoidoscopy 
 Colonoscopy 
 Double Contrast Barium Enema 
 Abdominal Surgery 




 Antibiotic.  
 A controversial drug class is that of antibiotic. Although antibiotics are the culprit of a 
change of colonic microflora as in the Clostridium Difficile infectious process, research 
regarding the use of antibiotics and probiotics in the treatment of IBS has grown exponentially. 
Rifaximim, which is a non-absorbed, broad-spectrum, antibiotic specific for enteric pathogens, is 
often reported as able to improve symptoms of bloating, diarrhea, abdominal pain, and 
constipation. The cause of this benefit remains unclear but is attributed to the suppression of gas 
producing bacteria in the colon.   
 Bulking Agents.  
 Where antibiotics are thought to suppress gas production bulking agents are known for 
increasing gas pains and cramping sensations. In terms of IBS-D bulking agents like Psyllium, 
Methylcellulose or Polycarbophil 
 may be used (these can also be effective in IBS-C). If severe enough an antidiarrheal like 
Loperamide may be of assistance.  
 Antidepressants.  
 Antidepressant drugs are found to be beneficial in patients with neuropathic pain and 
have a side effect of slowing colonic transit time therefore Tricyclic antidepressants – 
amitrityline and nortriptyline, Selective Serotonin Reuptake Inhibitors (SSRI) including but not 
limited to Fluoxitine, Paroxitine, and Citalopram, and Selective Norepinephrine Reuptake 
Inhibitors (SNRI) including Duloxetine are proposed to assist in IBS-D and abdominal pain. 
 Laxatives.  
 The pain associated with IBS-C may be helped with Osmotic laxatives including: 
Lactulose, Milk of Magnesia, or Polyethelene Glycol, or Stimulant laxatives such as Cascara 




Segrada or Senna. Tegaserod, a 5-hydroxytryptamine (serotonin) 4 receptor agonist (5-HT4), 
which stimulated the release of neurotransmitters causing an increase in colonic motility was 
removed from the market in March, 2007 related to cardiovascular side effects. However, it was 
reintroduced with restricted use for IBS-C only in 2007 and is being marketed for women < 55 
years-old. It was followed with another prokinetic, Lubiprostone, which is approved for use in 
women > 18 years-old. Lubiprostone is a chloride channel activator that increases chloride ions 
in the gut causing an increase in sodium and water in the gut to maintain balance. 
 Antispasmodic Agents.  
 An opposite effect of laxatives is created with antispasmotics. IBS with abdominal pain 
(gas, bloating) is historically treated most often with Antispasmodic agents such as Hycosamine, 
or Dicyclomine; of which hycosamine is also known to decrease fecal urgency with associated 
pain. Its method of action is the blockade of acetylcholine at parasympathetic sites in smooth 
muscle, secreatory glands, and CNS eliciting an antispasmodic and antidiarrheal effect. 
Additionally 5-hydroxytryptamine (serotonin) 3 receptor antagonists (5-HT3) such as Alosertron 
predominantly or Ondansetron have been utilized due to their ability to affect visceral afferent 
activity in the gastrointestinal tract via the enteric nervous system. There method of action is to 
block 5-HT3 receptors, which if stimulated cause hypersensitivity and hyperactivity of the colon. 
These medications have been used after failure on other pharmacological regimes as they are 









 Probiotics is emerging as a promising treatment option for management of IBS 
symptoms. Probiotic usage historically has been proven beneficial in the treatment of 
Inflammatory Bowel Disease including Crohn’s Disease and pouchitis. Probiotics work on the 
digestive microflora which are the plants that can be seen microscopically and inhabit the colon 
to maintain an ecological balance and prevent overgrowth of any one plant type.  Probiotics or 
“good bacteria” contain live microorganisms which are utilized by the human body to restore the 
balance of microflora in the digestive tract (Encarta Online Dictionary, 2010).  
 Probiotics work in the colon. The colon is sterile at birth and is colonized by swallowed 
bacteria within one week from birth. There are typically 10 9 -1010 organisms per gram of stool. A 
mixture of bacteria is necessary in the colon as it breaks down cellulose and waste material, 
deconjugates bile salts, synthesizes vitamin K, and controls the overgrowth of any one 
bacterium. Conversely, bacteria are known to manufacture gas, produce toxins which can cause 
colitis or diarrhea, and make ammonia. The mechanisms of action for probiotics according to 
Sartor (2004) include: inhibiting pathogenic enteric bacteria, and improving epithelial and 
mucosal barrier function. Pathogenic enteric bacteria are inhibited through probiotics decreasing 
the luminal pH, causing the secretion of bactericidal proteins, eliciting colonization resistance, 
and the blockage of epithelial binding resulting in the inhibition of epithelial invasion. Epithelial 
and mucosal barrier functions are improved by probiotics through the production of short chain 
fatty acids, enhanced mucus production and increased barrier integrity. Probiotics are also used 
to reduce intestinal permeability and are being researched regarding their ability to reduce pro-
inflammatory cytokines. 




 Normal gut flora may be altered in a variety of ways including: illness, stress, antibiotic 
treatment, physiologic alterations of the gastrointestinal system, or changes in diet. Quigley and 
Flourie (2007) propose that probiotics are also able to assist the immune response and reduce 
cytokine production, which could possibly hinder an autoimmune response. American College of 
Gastroenterology Task Force (2009) has taken the stance that “there is evidence suggestive that 
some probiotics may be effective in reducing overall IBS symptoms but more data are needed” 
(p. S1). 
 A basis for the data being gathered is that the microflora is known to be important for 
intestinal function and changes in GI microflora have been found in people with IBS (Malinen et 
al., 2005 and Kassinen et al., 2007). Shanahan (2007) proposes that it is an uncertainty if the 
changes seen in microflora of IBS patients are its cause or effect. The theory of infectious 
gastroenteritis precipitating IBS supports the idea of changes in microflora are a precipitating 
event. 
 Although there are a variety of theories of the initiation of IBS symptoms the most 
common complaint by persons affected is that of abdominal pain and bloating. The majority of 
treatments to date have focused on diarrhea and constipation symptoms leaving abdominal pain 
often untreated. The use of probiotics has flourished in an effort to control pain and bloating 
symptoms. Prior to the use of probiotics people with predominant abdominal pain were 
encouraged to eliminate gas producing foods, given anticholinergic anti-spasmodic drugs, or 
were given a tricyclic antidepressant (nortriptyline) to delay intestinal transit time and blunt 
visceral sensation.    
 The use of probiotics is not a new avenue of research as complementary and alternative 
medicine has embraced the role of intestinal microbes for years. Sartor (2004) after studying 




probiotics clinically in relation to Inflammatory Bowel Disease, found that probiotics (live 
microbial supplements), prebiotics (dietary supplements that promote the growth of beneficial 
bacteria) and symbiotics (a combination of probiotics and probiotics) are able to restore 
beneficial Lactobacillus (L.) and Bifidobacterium (B.) to the colon. Further studies have found 
Lactobacillus not as effective (O'Mahony et al., 2005).  Bifidobacterium is the most promising 
along with VSL#3 (VSL Pharmaceuticals, Fort Lauderdale, FL) which was developed based on 
findings that people with IBS have decreased Coliforms, Lactobacilli, and Bifidobacteria 
(Balsari, Ceccerelli, Dubini, Fesce, & Poli, 1982) .  VSL#3 contains 450 billion viable 
lyophilized bacteria, including Bifidobacterium (B. longum, B. infantis, and B. breve) 
Lactobacillus (L.acidophilus, L. casei, L. delbrueckii subspecies bulgarius, and L. plantarum), 
and Streptococcus salvarius subspecies thermophilus (Wald & Rakel, 2008).  
 Several trials regarding the efficacy of probiotics are available for review; however, five 
of the most cited trials will be reviewed here (Table 3 located in Appendix A). They are from 
Ireland, (O'Mahony et al., 2005) Finland, (Kajander et al., 2008) United States of America, (Kim 
et al., 2003) United Kingdom, (Whorwell et al., 2006), and France (Guyonnet et al., 2007).  
Although studies consisted of men and women, the majority of the study participants were 
women, with one study that was women exclusively (Whorwell et al., 2006). All of the studies 
included only participants that met the Rome II Criteria for IBS. They also all further stratified 
the IBS participants in terms of IBS-C, IBS-D or IBS-M. The trials varied in terms of the type, 
strength, dose and number of probiotics utilized. 
 O’Mahoney et al (2005) conducted a small 80 subject randomized double blind study. 
After inclusion criteria 67 subjects completed the study.  The study looked at the response of 
symptoms and cytokine ratios in IBS patients after they received therapy of either L. salvarius 




UCC4331 or a B. infantis 35624. Of the participants, 64% were women and 36% were men. All 
were recruited via advertising from Gastroenterology clinics. For 8 weeks each group received 
1x1010   colony-forming units (cfu) bacterial cells in a malted milk drink, or a plain malted milk 
drink with placebo. Using Likert scales and Visual analog scales (VAS) scores were recorded 
daily regarding abdominal pain/discomfort, bloating/distension, and bowel movement difficulty 
for the 8 weeks of the trial and the 4 weeks following. A quality of life assessment tool, 
microbiologic stool studies, and blood sampling to determine the release of the cytokine 
interleukin-10 and interleukin-12 were done at the beginning and end of the treatment portion of 
the study. This global assessment of symptoms found improvement in all areas except bowel 
movement difficulty for the participant’s receiving B. infantis 35624. At baseline interleukin-10 
and interleukin-12 a monitoring tool for an anti-inflammatory state was elevated and was found 
to normalize to a pro-inflammatory state after intake of B. infantis 35624. Four subjects reported 
adverse reactions as follows: one had a one-time epistaxsis which spontaneously resolved, one 
had chest pain attributed to anxiety, one was hospitalized with unstable angina, and one was 
hospitalized for IBS-C exacerbation. There were no clinically significant changes found in any of 
the subjects during the study length in terms of serum blood count, chemistry or immunoglobulin 
levels. The small size of this study and the short duration limited the ability to generalize results; 
however, the researchers were able to show superiority of B. infantis 35624 in the reduction of 
the cardinal IBS symptoms. It was hypothesized that the probiotic may have immune-modulating 
effects. The study results established that there may be an inflammatory component to IBS. 
Furthermore, since there was no change in stool patterns this probiotic may be utilized in all 
subtypes of IBS. 




 A study by Kajander, et al., (2008) looked at 86 participants with 93% of them being 
women were recruited from primary care by a certified endoscopist. The participants ages ranged 
from 20-65. This was a randomized double blind placebo-controlled, parallel-group 5-month 
study where participants received an 80% lactose free, milk-based drink of either placebo or a 
multispecies probiotic supplement which included: L. rhamnosus GG, L. rhamnosus Lc705, 
Propionibacterium freudenreichii ssp., shermanii JS and B. animalis ssp. Lactis Bb12. The total 
cfu in each probiotic drink was 1x10 7. All participants were allowed to continue on their current 
IBS medications; however they were not allowed to take any other probiotics or eat foods with 
probiotics in them. Analysis was based on a quality of life diary, a Likert scale measuring 
intensity of symptoms, (abdominal pain, distension, flatulence, and rumbling) bowel habits, and 
fecal and blood samples including C-reactive protein and cytokines. There were 43 subjects in 
each group. Ten in the probiotic group and 15 in the placebo group reported adverse reactions 
the majority of which were gastrointestinal or respiratory symptoms (probiotic 62% and placebo 
65%). Further findings in the probiotic group were an eye operation, carotid artery 
atherosclerosis, an inflamed mole, cystitis and tenosynovitis. All but four of the placebo 
gastrointestinal complaints were found to have no association with the study. Confidence 
intervals of 95% were used. The Likert symptom score showed a 37% reduction of symptoms in 
the probiotic group compared to a 9% reduction in the placebo group. In terms of bowel habits a 
lessening of distension (P=0.023) and abdominal pain (P=0.052) was found in the probiotic 
group. No change was found in the form of bowel movements in either group. The quality of life 
data addressed bowel symptoms, fatigue, activity limitations, and emotional function. The 
probiotic group had a median 0.62 point (95% CI: 0.37-0.86) beneficial effect on the bowel 
symptoms domain. Also, a stabilization of intestinal microbiota was found when a high 




similarity index between two points in time was noted. The probiotic group rose and the placebo 
group decreased. The difference between the groups (-4.8; 95%CI: -6.59 to -2.54) was 
significant (P= 0.0015). In terms of the inflammatory markers no significant changes were noted 
in either group. As with the O'Mahony et al. (2005) study beneficial effects of probiotic 
supplementation included a stabilization of intestinal microbiota. Conversely, there is no change 
in inflammatory markers found in this study which is a limitation symptom severity. There is an 
increase in quality of life. Although this study found probiotics to be a safe alternative for the 
management of IBS symptoms and stabilization of microbiota it is again a small study and 
relatively short duration of time. 
 Kim, et al., (2003) used a parallel group, double-blind, placebo controlled randomized 
study of 48 participants with 94% of them being female between 18-75 years-old. They were 
recruited through both primary and secondary care center. Inclusion criteria were IBS-D and  
bloating symptoms. A total of 25 participants were then randomized with N=13 receiving 
placebo and N=12 receiving VSL#3 in a powder form for this ten week study. No other IBS 
medications were permitted. Participants recorded relief of symptoms and used the Bristol stool 
scale to monitor stools. Ease of passage was recorded on a Likert scale. There were no adverse 
reactions with VSL#3. Five participants took antibiotics during the study for other ailments. This 
study found that VSL#3 had no effect on colonic transit time; however, it was able to decrease 
bloating symptoms. Abdominal bloating was reduced (P1/4 0.046) in the VSL#3 group 13.7 with 
a CI 95%, 2.5-24.9, but not in the placebo group (P ¼ 0.54) with a 1.7 CI 95%, 7.1-10.4. 
Limitations of this study include the small sample size and lack of ability to generalize the 
results, but it statistically has shown a reduction in IBS bloating symptoms. 




 A comparatively large-scale, multi-center, randomized, double-blind, placebo-controlled, 
dose ranging study was conducted by (Whorwell, et al., 2006). This study had 362 participants 
ranging in age from 18-65 years-old. Participants were recruited from 20 primary care sites. 
Participants were randomized to receive one of four capsule treatments: B. infantis 35624 at 
either 1x10 6 or 1x10 8  or 1x10 10  cfu concentration or placebo. The capsule was taken once daily 
for four weeks. They were then followed for two weeks after the study. Daily symptoms were 
recorded using voice prompting over the telephone. Rescue medication of bisacodyl 5mg for 
constipation and loperamide 2 mg for diarrhea were allowed and tracked. No significant 
treatment effect was found. At the end of each week a global assessment of symptom 
management was recorded. Participants completed an IBS specific quality of life questionnaire 
and the Hospital Anxiety and Depression Scale. Analysis of these showed no changes during the 
4 week study. Seventeen participants withdrew from the study related to adverse events and there 
was no difference in the amount of adverse events between the placebo and medicated groups. 
Probiotics were not found to change stool form or frequency which render them useful to all 
subtypes of IBS. In particular the dose of B. infantis 35624 1x10 8 was found to provide the most 
benefit for a variety of symptoms including pain, bloating, gas, and had increased bowel habit 
satisfaction. The 1x10 10 capsule showed results similar to placebo and at no time was placebo 
ever more effective than probiotic at any dose. These results are significant because they showed 
improvement in more than one area and typical IBS pharmaco-management is achieved with one 
drug for one symptom. In addition, positive results were obtained in the primary care setting. As 
with similar studies quality control of the probiotic is in question as no standards exist. The 
effect waned after discontinuation leaving the length of the study a further limitation. 




 Another multicenter study was conducted by Guyonnet, et al., (2007). It encompassed the 
primary care setting consisting of 35 centers. The study was a randomized, double-blind, 
controlled trial with 274 IBS-C participants followed over a six week period. The participants 
ranged from 18-65 years-old with 199 of the participants being women. No other probiotics or 
prebiotics were allowed during the study. The test product was B. animalis DN-173 010 
(Activia) with 1.25 x 10 10 cfu per container of yogurt together with the two classical yogurt 
starters S. thermophilus and L. bulgaricus (1.2 x 10 9  cfu/container. The control was a heat 
treated yogurt which contained non-living bacteria. Both products were prepared by Danone 
Research Palaiseau, France. Participants completed a health-related quality of life questionnaire 
specific to IBS symptoms prior to the study and at three and six weeks. Symptoms of bloating, 
abdominal pain, and stool characteristics were evaluated using a Likert scale. There was 
improvement in bloating, abdominal pain, and global digestive symptoms (P< 0.05) at six weeks 
in the test group but not the control group. Bloating and abdominal pain improved (P=0.03) 
higher at week three in the test group. Further symptom improvement did not change between 
the groups. Over the six week period the participants who had <3 BM/week had an increase in 
stool frequency (P<0.001) up to a mean of six BM/week with results starting at week one. Ten 
subjects were in the control group, and 13 in the test group. A total of seven subjects withdrew 
reporting minor adverse events. The use of probiotic food was found to be statistically 
significant, in terms of the health-related quality of life.  Health-related quality of life scores 
were relatively unchanged in other studies. The study also demonstrated the ability to increase 
the amount of stool per week in IBS-C patients. Limitations include a high placebo response rate 
which has been reported from 40-45% and is related to the subjective questions involved in the 
data collection, and the study was conducted by the manufacturer of Activia.  




 These and other studies show probiotics exhibit promise in effectively reducing global 
IBS symptoms. Unfortunately probiotics are not FDA approved because they are not a drug. Due 
to this they are not covered under insurance and do not have the quality control of medications. 
Of note Proctor & Gamble Company has provided the manufacturing conditions for B. infantis 
in studies. It is known that Lactobacilli does not appear to be effective, while B. infantis 35624 
and some combinations do exhibit efficacy in symptom management. The lack of stool 
alteration, aside from the B. animalis combination used by Guyonnet (2007), renders probiotics 
efficious in all subtypes of IBS. Furthermore, the ability of probiotics to effect more than one 
symptom of IBS is superior to the one symptom one drug approach of typical pharmacotherapy. 
Probiotic foods have the potential to relieve multiple symptoms and improve quality of life as do 
those in pill/capsule/powder form. The American College of Gastroenterology Task Force (2009) 
has given probiotics a weak recommendation relating to the low quality of the evidence. Studies 
remain ongoing and no single species, strain, or preparation has been identified as the drug of 
choice. The confusion surrounding the efficacy of probiotics is further fueled by the varied 
duration of treatments and different follow-up regimes. Probiotics are all considered safe with no 
adverse reactions, making the choice one of desired outcomes and patient preference.  
 Probiotics are a viable option for IBS sufferers, based on their desired outcomes, whether 
they have failed on pharmacologic management or not. Although they have been embraced by 
the Alternative Medicine community for years they are gaining recognition in the arena of 
evidenced-based medicine.  Attention should be given to the support and empowerment of the 
patient regarding probiotic usage through the provision of education and counseling. 
 
 




Education and Counseling 
  Education and counseling emphasis should be based on relief of IBS symptoms and an 
increase in health-related quality of life. Although a menu of phamacotherapeutic options exists 
for the treatment of IBS; patients typically do not experience relief of abdominal bloating, gas 
and pain. They should be informed of the various options for treatment including: bulking 
agents, 5-HT4 agonists, osmotic laxatives, stimulant laxatives, prostone, antidiarrheals, 5-HT3 
antagonist, antibiotic, antispasmodic, tricyclic antidepressant, SSRI, SNRI and probiotics. 
Providers should explain the benefits and side effects of all drugs and explain that research is 
ongoing regarding the use of probiotics. Probiotics, as with medications, requires that dose and 
timing be titrated based on individual experience.   
Education on use of medications 
 There is no standard of care in terms of the phamacotherapy of IBS; treatment is based on 
symptom management and highly individualized. A review of typical medications has been 
conducted in this paper with a more extensive review of research focusing on the use of 
probiotics. Most importantly there are no serious adverse reactions with the use of probiotics and 
studies suggest that Bifidobacterium infantis 35624 provides improvement of symptoms in IBS. 
Due to the lack of prolonged studies regarding probiotics the use, dose and after effect of these 
agents remains largely anecdotal. Furthermore, probiotics are not considered a medication and do 
not fall into a federally regulated classification. Considering the plethora of information 
accessible on the internet; patients should be counseled on which strain of probiotic would be 
most useful prior to purchasing them over the counter. Currently, Align is a gastroenterologist 
recommended, patented, daily dietary supplement. It is sold over the counter and is a capsule that 
is taken once daily. It contains Bifidobacterium infantis 35624. It is not FDA approved for the 




treatment of IBS at this time, but is the most accessible for providers wanting to recommend 
treatment with probiotics. Align can be found at retail and drug stores. The cost of Align varies, 
with an approximate cost of $30 for 28 capsules. Probiotics are an option, along with the variety 
of pharmacotherapeutic  options, which the primary care provider can safely recommend. 
Counseling  
  There is no known prevention of IBS and to date there remains only management of 
symptoms with adjunctive therapies include cognitive, behavioral or diet modalities. IBS is a 
chronic condition with periods of exacerbation often associated with periods of stress. Although 
it does not have significant morbidity or mortality it can be disabling. Its affects are felt 
physically, psychologically, socially and economically. Reassurance of absence of organic 
pathology and that it will not alter their life expectancy is essential for the patient.  
 The acceptance of reassurance is achieved through the provider-patient relationship. This 
relationship is paramount in the treatment of IBS. Time constraints, such as those imposed by 
managed care regulations, on visit length make the establishment of a trusting relationship 
difficult (Wald & Rakel, 2008). Frequent follow-up visits in the primary care setting where a 
working partnership is established allows the patient to share openly without fear of judgment 
and allows time for teaching during the office visit.  
 Van Tilberg et al. (2008) posit that although patients continue with the traditional western 
medicine approach approximately one-third of IBS patients are seeking alternative medicine. 
Current research on all forms of Complementary Alternative Medicine (CAM) is promising. A 
detriment to CAM use is the published placebo response rates. In their meta-analysis of placebo 
response in CAM trials of irritable bowel syndrome Dorn et al. (2007) postulate that due to the 
response rate being similar to that of conventional medicine trials it is not enhanced in CAM. 




CAM is typically an out of pocket expense for the patient leaving those in the lower 
socioeconomic classes less access. Providers are often not recommending these treatments; 
however, they become part of the treatment plan through the patient’s use of them and should be 
documented accordingly. The majority of CAM is focused on stress reduction or cortical 
influences and includes having a hobby, exercising, meditation, biofeedback, cognitive behavior 
therapy, acupuncture and chiropractor (Wald, 2003). Cognitive behavior therapy is based on the 
idea that the mind can be taught to control functions of the body and research is documenting its 
positive effect (Wald & Rakel, 2008). There are also herbal remedies including studies on the 
use of peppermint. Although the research in these areas is growing and the results are positive 
they remain subjective in nature.  
 Subjective assistance can also be found through dietary counseling and includes 
educating the patient regarding fiber and fluid consumption. Increasing the amount of fiber in the 
diet is helpful for some patients while it precipitates increased bloating and distension in others. 
The recommended dietary intake of fiber is 25 grams; however, fiber supplements can also be 
utilized. (Polycarbophil compounds like Citrsucel and FiberCon may produce less flatulence than 
psyllium compounds like Metamucil). Drinking an adequate amount of water daily, 64 ounces, 
will assist in preventing constipation, and the avoidance of caffeine will decrease dehydration 
and feelings of anxiety.  
 Literature has mixed results regarding dietary modifications beyond fiber and fluid 
consumption recommendations. The continuum ranges from the elimination diet to no change is 
useful. Atkinson, Sheldon, Shaath, and Whorwell (2004), found clinical symptom improvement 
in subjects that eliminated foods they were found to have IgG sensitivity to. Patients report relief 
from simple modifications such as reporting a reduction in bloating and distention after avoiding 




gas-producing foods like beans, onions, broccoli and cabbage, as well as eliminating foods that 
are high in fat. An avoidance of the sugar substitute sorbitol which has known side effects of 
bloating and diarrhea is effective (Longstreth et al., 2006).  Lactose intolerance is seen in 40% of 
people with IBS. Often these people have no symptoms of intolerance until after age 30. These 
people should avoid lactose to lessen gas and bloating. Dietary adaptations should be made 
slowly allowing the body time to adjust. Further recommendations include slowing the rate at 
which one consumes food (Longstreth et al., 2006) which will avoid overeating and avoiding 
gum or carbonated beverages to lessen the swallowing of air. Food diaries may be helpful in 
determining causative agents. Whether the patient changes their diet or uses other adjuncts 
including probiotics the focus should remain on increasing comfort and providing for optimal 
health-related quality of life. 
Implications for Practice 
 IBS changes in health-related quality of life account for a significant amount of primary 
care and gastroenterology visits. The diagnosis and treatment of IBS is costly yet ongoing 
research into this syndrome and its management is promising. The cause of IBS is unknown; 
therefore, there is no cure, only management of symptoms. Recognition of the mind body 
connection is helpful for providers. The impact of discomfort and distress on the patient may 
wax and wane over the years and at times may be disabling. Some estimates include that it is 
second to the common cold for work/school days missed. As previously stated, it is known that 
not all people who fit the Rome Criteria for diagnosis seek medical attention, and women are 
more likely to seek care than men.  
 Several algorithms based on the Rome Criteria exist to assist the provider in determining 
the diagnosis of IBS. Initially patients present with an alteration in bowel habits and associated 




abdominal pain. The first step is to determine if they meet the Rome criteria, otherwise it is 
merely a matter of appropriate symptom evaluation and management. If they do meet the Rome 
criteria the next step is to determine if they have any of the red flag warning signs including: 
rectal bleeding, anemia, weight loss, fever, family history of colon cancer, onset of first 
symptoms after 50 years-old, or a major change in symptoms. If they have positive warning 
signs further evaluation is needed to find the cause. This ongoing evaluation may include a 
colonoscopy or other symptom specific diagnostic testing. If all of this testing is negative a final 
diagnosis of IBS may be confirmed. Conversely, if there no warning signs a hemoccult stool 
sample or FIT test and serologic celiac sprue testing should be the next step. If either of these is 
positive a full evaluation should be completed recognizing that a diagnosis of IBS may still 
result. If, however, these are both negative no further evaluation is needed and the diagnosis of 
IBS is confirmed as seen in Figure 2 in Appendix C. 
 Obtaining a diagnosis of IBS is challenging even with the guidance of algorithms, yet 
treatment of this syndrome is even more challenging. Currently, symptom management based on 
IBS subtype sometimes with multiple agents is the norm. Although antispasmodics have been 
reported as effective, the choice of pharmacotherapy remains largely subjective based on patient 
response and ultimately the provider patient relationship influences the choices offered. 
Probiotics are an emerging therapy option with no serious adverse reactions. Probiotics should 
not be used in immune-compromised patients as they have not been studied in this group. 
Probiotics ability to improve quality of life for the patient by way of reducing abdominal pain 
and bloating, passing of flatus, and incomplete evacuation/straining symptoms is significant. 
Clearly more and larger clinical trials are necessary for the widespread acceptance of probiotics 
in the scientific community; however, existing research is providing the evidenced-based 




groundwork for their acceptance. Further complications in probiotic dosing are that no single 
species, strain, preparation has been identified as the probiotic of choice and the varied duration 
of treatment and follow-up have contributed to the confusion of their efficacy. 
 Probiotics are an enigma in many ways, but based on studied patient responses they work 
and they do not harm or worsen the condition of the patient. The cost of treatment of IBS in the 
US excluding indirect expenses such as lost productivity, lost wages, over the counter 
medications, and co-payments reaches into the billions. Probiotics, in particular Bifidobacterium 
infantis, appear to be more than an added expense in the treatment of IBS. By providing an 
increase in the patient’s health-related quality of life they have the potential to significantly 
reduce IBS related healthcare costs and provide a treatment resource for the primary care. 
Furthermore, the patient has an established relationship with their primary care provider and 
through therapeutic listening and communication the patient can have their symptoms validated, 
diagnosed and managed in the primary care setting. Ultimately more research is needed towards 
the standardized use of probiotics and the management of the IBS patient in primary care. 
Recommended Internet Resources 
 Numerous websites are available to provide information on IBS and its management. The 
American Gastroenterology Association has a link on their homepage that takes one to IBS 
specific information (American Gastroenterology Association, 2009) for patients. This site 
includes information regarding the basics of IBS, symptoms, diagnosing, treatment, living with 
IBS and the relationship between diet, stress and IBS. There is also an option to order brochures 
and DVD’s for your patients at the end of the information. 
 The American College Of Gastroenterology website (American College of 
Gastroenterology Task Force, 2008) is similar to the American Gastroenterology Association site 




with a strong commitment to providing accurate unbiased and up-to-date health information. It is 
an organization with a membership of over 10,000 individuals from 80 countries. This site 
proposes a commitment to serving the clinically oriented digestive disease specialist with an 
emphasis on scholarly practice, teaching and research. It is organized by disease and is 
developed by the American College of Gastroenterology physicians. 
 The World Gastroenterology Organization is a federation of over 109 societies and has a 
useful website for practitioners as well (World Gastroenterology Organization, 2009). It provides 
a global perspective regarding IBS. There are monthly research reviews and success stories from 
over 40 countries. The IBS guidelines link is easily referenced and includes clinical cascades for 
treatment at every resource level. Furthermore, they have a test practitioners can utilize to 
diagnose IBS and a list of patient frequently asked questions. A similar international site 
focusing on education and research is the International Foundation for Functional 
Gastrointestinal Disorders (International Foundation for Functional Gastrointestinal Disorders, 
2011). It is an excellent site to refer people diagnosed with IBS due to the Irritable Bowel 
Syndrome Self Help And Support Group (2011). It comprises information, blogs, and offers of 
support through self help or in a group. 
Finally, The National Institute for Diabetes, Digestive and Kidney Disorders is a federal 
health agency that offers a booklet on IBS as well as other resources for patients on digestive 
health topics (National Digestive Diseases Information Clearinghouse, 2007). Also, they sponsor 
a telephone hotline 301-654-3810 through the National Digestive Disease Information 
Clearinghouse. 
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